There are 2789 resources available
464P - Exome sequencing of ctDNA portrays the mutational landscape of patients with relapsing colon cancer and indicates new actionable targets
Presenter: Noelia Tarazona
Session: ePoster Display
465P - Identification of actionable alterations in primary colorectal tumors using NGS-based comprehensive genomic profiling
Presenter: Alfred KY Lam
Session: ePoster Display
522P - Risk mitigation of ocular toxicities due to antibody drug conjugates (ADCs) in novel early-phase clinical trials
Presenter: Khobe Chandran
Session: ePoster Display
467P - Monocyte to red blood cells ratio (MRR): an innovative haematologic prognostic parameter in FOLFIRI-aflibercept treated patients: A subgroup analysis from the DISTINCTIVE trial
Presenter: Eleonora Lai
Session: ePoster Display
524P - A phase I, open-label, dose-escalation trial of BI 1701963 in patients (pts) with KRAS mutated solid tumours: A snapshot analysis
Presenter: Melissa Johnson
Session: ePoster Display
525P - Efficacy, safety, pharmacokinetic (PK) and pharmacodynamic (PD) data from phase I dose escalation of a novel therapeutic peptide, ST101, targeting the oncogenic transcription factor C/EBPβ, in patients (pts) with advanced and metastatic solid tumors
Presenter: Meredith Mckean
Session: ePoster Display
526P - Pharmacodynamic evidence for WEE1 target engagement in surrogate and tumor tissues from a phase I study of the WEE1 inhibitor ZN-c3
Presenter: Pavani Chalasani
Session: ePoster Display
527P - Phase I study of the novel prodrug MIV-818 in patients with hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma (iCCA) or liver metastases (LM)
Presenter: Debashis Sarker
Session: ePoster Display
528P - Discovery of ZN-d5, a potent BCL-2 inhibitor with improved selectivity for BCL-2
Presenter: Joseph Pinchman
Session: ePoster Display